Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’

We recently published 10 Big Names With Explosive Growth. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best performers on Wednesday.

Intellia rallied to a new all-time high on Wednesday, as investors took path from two investment firms’ “buy” recommendations for its stock.

During the session, Intellia Therapeutics, Inc. (NASDAQ:NTLA) soared to an all-time high of $26.46 before paring gains to end the day just up by 19.72 percent at $24.47 apiece.

In a market note, Zacks Research upgraded its stock to a “buy” recommendation amid an upward trend in earnings estimates from Wall Street analysts.

“Rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company’s underlying business. And investors’ appreciation of this improving business trend should push the stock higher,” it said.

Meanwhile, Intellia Therapeutics, Inc. (NASDAQ:NTLA) also earned an “outperform” rating and a price target of $33 from JMP Securities, with the upgrade buoyed by a strengthened outlook for its hereditary angioedema (HAE) program.

According to the investment firm, the company’s drug candidate, Ionvo-Z, could capture a 19-percent market share and potentially translate to $2.8 billion market opportunity.

While we acknowledge the risk and potential of NTLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NTLA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.